Explainer
Common myths about GLP-1 weight-loss drugs
By the TreatmentMD editorial team
Key takeaways
- Taking a GLP-1 isn't cheating. These medicines work with your body's own hunger signals, alongside healthier eating and more movement.1U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.All sources
- They're usually a long-term treatment, and how long you stay on one is a decision you make with your clinician.2National Institute of Diabetes and Digestive and Kidney DiseasesSourceNIDDK. Prescription Medications to Treat Overweight & Obesity. Last reviewed June 2024.Open the source All sources
- You don't need diabetes or an in-person visit to get started, and brand-name prices now start at $149 a month without insurance.3Novo NordiskSourceNovoCare. Wegovy® (semaglutide) self-pay and list prices. Checked October 6, 2026.Open the source All sources
By the TreatmentMD editorial team
GLP-1 medicines are everywhere right now. About 1 in 8 U.S. adults are taking one, for weight loss or for a condition like diabetes.4KFFSourceKFF. Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition. November 2025.Open the source All sources
With that much buzz comes a lot of myths. Some make GLP-1s sound like a magic fix, and others make them sound like cheating.
Here are the ones we hear most, and what's actually true, so you can decide whether a GLP-1 is worth exploring.
01Willpower
Is taking a GLP-1 the easy way out?
No. Obesity is a chronic disease that affects more than 4 in 10 U.S. adults, and the American Medical Association has recognized it as one since 2013.2National Institute of Diabetes and Digestive and Kidney DiseasesSourceNIDDK. Prescription Medications to Treat Overweight & Obesity. Last reviewed June 2024.Open the source All sources5American Medical AssociationSourceAmerican Medical Association. Policy H-440.842, Recognition of Obesity as a Disease. Adopted June 2013.Open the source All sources
Most people already sense that willpower isn't the whole story. In one national survey, about two-thirds of Americans said willpower alone usually isn't enough to lose weight and keep it off.6Pew Research CenterSourcePew Research Center. How Americans View Weight-Loss Drugs and Their Potential Impact on Obesity in the U.S. February 26, 2024.Open the source All sources
Your genes, sleep, stress, health conditions and some medicines all shape your weight, not just what you eat.7National Institute of Diabetes and Digestive and Kidney DiseasesSourceNIDDK. Factors Affecting Weight & Health. Last reviewed May 2023.Open the source All sources
Your body also pushes back when you lose weight. It tends to burn a little less energy and make you hungrier.8Endocrine SocietySourceEndocrine Society. Endocrine Society issues Scientific Statement on obesity's causes. June 26, 2017.Open the source All sources That's part of why dieting alone is so hard to keep up.
A GLP-1 works with those signals. It acts like a natural hormone that helps control appetite, so you feel full sooner and stay satisfied longer.1U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.All sources
The medicine quiets the hunger, and the healthy habits are still yours. That's why GLP-1s are approved alongside a reduced-calorie diet and more physical activity.1U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.All sources
In short: A GLP-1 is a treatment, not a shortcut. It turns down the hunger, and you do the rest.
02How long
Do you have to take a GLP-1 forever?
Not necessarily, but it's usually a long-term treatment. GLP-1s work while you take them, much like medicine for high blood pressure.9Cleveland ClinicSourceCleveland Clinic. How Long Should You Be on a GLP-1? May 1, 2026.Open the source All sources
You can stay on one as long as it's helping and you feel well.2National Institute of Diabetes and Digestive and Kidney DiseasesSourceNIDDK. Prescription Medications to Treat Overweight & Obesity. Last reviewed June 2024.Open the source All sources
If you stop, it's common for some of the weight to come back. That's why it's worth planning the long run with your clinician.2National Institute of Diabetes and Digestive and Kidney DiseasesSourceNIDDK. Prescription Medications to Treat Overweight & Obesity. Last reviewed June 2024.Open the source All sources
It's rarely all or nothing, though. In one study, people who stopped were still lighter on average a year later than when they started.10Diabetes, Obesity and MetabolismRandomized trial · 2022STEP 1 extensionA year after stopping semaglutide, people had regained about two-thirds of the weight they lost, and were still 5.6% lighter on average than when they started.327 people · 120 weeks. Adults from STEP 1, followed for a year after treatment stopped.Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Wilding JPH, et al., 2022.Read the study All sources
Long-term doesn't have to mean the same dose forever, either. Some people move to a lower dose to maintain, and in a recent study, that kept much of the weight off.11The LancetRandomized trial · 2026SURMOUNT-MAINTAINA year after stepping down to 5 mg, people had kept about two-thirds of the weight they lost, against about two-fifths of those switched to placebo.378 people · 112 weeks: 60 weeks of weight loss, then 52 of maintenance. Adults with obesity, or overweight and a weight-related condition, who lost at least 5% in the first 60 weeks. Funded by Eli Lilly.Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Horn DB, et al., 2026.Read the study All sources
The habits you build along the way help too, whatever you decide.2National Institute of Diabetes and Digestive and Kidney DiseasesSourceNIDDK. Prescription Medications to Treat Overweight & Obesity. Last reviewed June 2024.Open the source All sources
How long you stay on one is your call, made with your clinician, based on how you're doing and what you want.
03Who it's for
Are GLP-1s only for people with diabetes?
No. Some GLP-1s are approved for type 2 diabetes, and others are approved for weight.
Wegovy®, Zepbound® and Foundayo™ are approved for weight loss. They help adults with obesity, or overweight plus a weight-related health condition, lose weight and keep it off.1U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.All sources
Ozempic® and Mounjaro® are the diabetes medicines. Ozempic® contains semaglutide, like Wegovy®, and Mounjaro® contains tirzepatide, like Zepbound®. Both are approved for type 2 diabetes rather than weight loss.1U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.All sources
That's why "Ozempic" gets used as a nickname for all of them, even though Wegovy® is the semaglutide approved for weight loss.
You don't need a huge amount of weight to lose, either. Clinicians usually look for a BMI of 30 or more. A BMI of 27 or more can qualify too, with a condition like high blood pressure or type 2 diabetes.2National Institute of Diabetes and Digestive and Kidney DiseasesSourceNIDDK. Prescription Medications to Treat Overweight & Obesity. Last reviewed June 2024.Open the source All sources
GLP-1s aren't right for everyone, so a licensed clinician reviews your health history to decide whether one fits.
04The options
Are all GLP-1s the same?
They're more like cousins than twins. They work on the same hunger signals, but they differ in what they're approved for and how you take them.1U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.All sources
Tirzepatide, the medicine in Zepbound®, works on two gut hormones instead of one.1U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.All sources
And they're not all shots anymore. The FDA approved two daily pills for weight loss: the Wegovy® pill in December 2025 and Foundayo™ in April 2026.12U.S. Food and Drug AdministrationSourceFDA. Drugs@FDA approval histories for Byetta®, Saxenda®, Ozempic®, Wegovy® and Foundayo™.Open the source All sources
| Approved for | How you take it | |
|---|---|---|
| Wegovy® | Weight, and lowering heart risk in people with heart disease | A weekly shot or a daily pill |
| Zepbound® | Weight, and sleep apnea in people with obesity | A weekly shot |
| Foundayo™ | Weight | A daily pill |
| Ozempic® | Type 2 diabetes | A weekly shot |
| Mounjaro® | Type 2 diabetes | A weekly shot |
The pills come with their own routines. You take the Wegovy® pill first thing in the morning with a little water, then wait 30 minutes before eating. Foundayo™ can be taken with or without food.1U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.All sources
05Results
Does a GLP-1 work the same for everyone?
No, and that's completely normal. Everyone's body responds a little differently.
In the large studies, everyone also got diet and activity coaching. On Wegovy®, people lost about 15% of their body weight on average over 68 weeks.13The New England Journal of MedicineRandomized trial · 2021STEP 1Mean body weight fell 14.9 percent on semaglutide against 2.4 percent on placebo over 68 weeks.1,961 people · 68 weeks. Adults with BMI 30 or above, or 27 or above with a weight-related comorbidity, without diabetes.Once-weekly semaglutide in adults with overweight or obesity. Wilding JPH, et al., 2021.Read the study All sources
On Zepbound®, they lost about 15% to 21% over 72 weeks, depending on the dose.14The New England Journal of MedicineRandomized trial · 2022SURMOUNT-1Mean body weight fell 20.9 percent at the 15 mg dose against 3.1 percent on placebo over 72 weeks.2,539 people · 72 weeks. Adults with BMI 30 or above, or 27 or above with at least one weight-related complication, without diabetes.Tirzepatide once weekly for the treatment of obesity. Jastreboff AM, et al., 2022.Read the study All sources
Those are averages, not promises. Some people lost a fifth of their weight or more, while others lost less than 5%.13The New England Journal of MedicineRandomized trial · 2021STEP 1Mean body weight fell 14.9 percent on semaglutide against 2.4 percent on placebo over 68 weeks.1,961 people · 68 weeks. Adults with BMI 30 or above, or 27 or above with a weight-related comorbidity, without diabetes.Once-weekly semaglutide in adults with overweight or obesity. Wilding JPH, et al., 2021.Read the study All sources
It takes time, too. Doses start low and step up over the first few months.1U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.All sources The studies measured results after well over a year, so think months, not weeks.
If the scale isn't moving after about three months on your full dose, your clinician can change your plan.2National Institute of Diabetes and Digestive and Kidney DiseasesSourceNIDDK. Prescription Medications to Treat Overweight & Obesity. Last reviewed June 2024.Open the source All sources
06Food and fitness
Can you eat whatever you want on a GLP-1?
You'll probably want to eat less, but what you eat still matters. With a smaller appetite, it helps to make every meal count.15Obesity PillarsSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025;15:100181.Open the source All sources
Most of the weight people lose is fat, but some is lean mass, which includes muscle.1U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.All sources That's true of any weight loss, not just on a GLP-1.15Obesity PillarsSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025;15:100181.Open the source All sources
A few simple habits help you keep your strength and feel your best:
Put protein on your plate
Include some at every meal, like eggs, fish, chicken, beans or Greek yogurt. Obesity and nutrition experts suggest about 80 to 120 grams a day, and your clinician can help you find your number.15Obesity PillarsSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025;15:100181.Open the source All sources
Lift something
Strength training at least three times a week, even with bands or your own body weight, helps protect your muscles.15Obesity PillarsSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025;15:100181.Open the source All sources
Keep moving
Aim for about 150 minutes of activity a week. A brisk walk of 20 to 25 minutes a day gets you there.15Obesity PillarsSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025;15:100181.Open the source All sources
Fill up on fiber
Fruits, vegetables, whole grains and beans help you feel full and keep your digestion happy.15Obesity PillarsSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025;15:100181.Open the source All sources
Drink enough water
Keep a water bottle handy through the day.15Obesity PillarsSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025;15:100181.Open the source All sources
07Cost
Do GLP-1s really cost over $1,000 a month?
That's the list price, the sticker price before any discounts, and there are much cheaper ways to pay. Wegovy®, for example, lists at about $1,349 a month.3Novo NordiskSourceNovoCare. Wegovy® (semaglutide) self-pay and list prices. Checked October 6, 2026.Open the source All sources
The makers now sell to people paying cash for a lot less. The Wegovy® pill starts at $149 a month. The Wegovy® pen is $199 a month for your first two fills, then $349.3Novo NordiskSourceNovoCare. Wegovy® (semaglutide) self-pay and list prices. Checked October 6, 2026.Open the source All sources
Zepbound® starts at $299 a month for the lowest dose, and Foundayo™ at $149.16Eli Lilly and CompanySourceLillyDirect. Zepbound® (tirzepatide) self-pay prices. Checked October 6, 2026.Open the source All sources17Eli Lilly and CompanySourceLillyDirect. Foundayo™ (orforglipron) self-pay prices. Checked October 6, 2026.Open the source All sources
Compounded versions usually cost less again. At the programs we rank, compounded semaglutide started at $49 to $179 a month. We checked in late September and early October 2026.
Insurance coverage varies by plan. Many online programs are cash-pay, so you don't need insurance to start, and some can check your coverage for you.
08Getting started
Can you get a GLP-1 online?
Yes. About 1 in 6 people who have taken a GLP-1 got it from an online provider.4KFFSourceKFF. Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition. November 2025.Open the source All sources
It's simpler than you might think. You answer some health questions, and a clinician licensed in your state reviews them.
If a GLP-1 is a good fit, your prescription goes to a pharmacy and your medicine ships to you.
Look for a program with a real clinician you can reach with questions, a licensed U.S. pharmacy, and clear pricing before you sign up.
We look at all of this when we rank programs, so you can start with a shortlist.
Frequently asked questions.
Are GLP-1s brand new?
Not at all.
Doctors have prescribed GLP-1 medicines since 2005, first for type 2 diabetes, and they've been approved for weight loss since 2014.
Semaglutide, the medicine in Ozempic® and Wegovy®, has been around since 2017.12U.S. Food and Drug AdministrationSourceFDA. Drugs@FDA approval histories for Byetta®, Saxenda®, Ozempic®, Wegovy® and Foundayo™.Open the source All sources
Is there a natural GLP-1, like berberine?
Not really.
Berberine, the supplement sometimes called "nature's Ozempic", works differently from GLP-1 medicines.18UCLA HealthSourceUCLA Health. What to know about berberine, the so-called "nature's Ozempic". October 22, 2025.Open the source All sources
In studies, it helped people lose only about 2 pounds on average.19International Journal of ObesityMeta-analysis · 2026Across 23 trials, berberine lowered body weight by 0.88 kg, about 2 pounds, more than the comparison groups.23 randomized trials of berberine in adults.The effect of berberine on obesity indices: a systematic review and meta-analysis. Elahi Vahed I, et al., 2026.Read the study All sources
And GLP-1 "patches" don't contain the medicine at all.20Cleveland ClinicSourceCleveland Clinic. Do GLP-1 Patches Work? What To Know. September 17, 2026.Open the source All sources
What is "Ozempic face"?
It's a nickname, not a medical term.
It describes how a face can look thinner after fast weight loss, from any cause.
It isn't a side effect of the medicine itself.
Steadier weight loss tends to be gentler on your face, and your clinician can help you set the pace.21Cleveland ClinicSourceCleveland Clinic. What Is 'Ozempic Face' and How To Prevent It. March 5, 2025.Open the source All sources
What about compounded GLP-1s?
Compounded semaglutide and tirzepatide are prepared by licensed pharmacies, and they usually cost less.22U.S. Food and Drug AdministrationSourceFDA. Compounding and the FDA: Questions and Answers. Content current as of September 16, 2025.Open the source All sources
A good program tells you which pharmacy makes yours, so you can look it up.
Here's how compounded GLP-1s work.
The bottom line
Most GLP-1 myths fade once you look at the facts.
These medicines work with your body's own hunger signals, and they're usually a long-term treatment.
Getting started is simpler and more affordable than it used to be.
When you're ready, compare your options on our ranking, and a licensed clinician will help you decide what fits.
By the TreatmentMD editorial team
Medical disclaimerThis content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting any weight-loss program or medication. Individual results may vary.
Sources
- 1FDA prescribing information for Wegovy®, Zepbound®, Foundayo™, Ozempic® and Mounjaro®: Indications and Usage; Dosage and Administration; Mechanism of Action.
- 2NIDDK. Prescription Medications to Treat Overweight & Obesity. Last reviewed June 2024. niddk.nih.gov
- 3NovoCare. Wegovy® (semaglutide) self-pay and list prices. Checked October 6, 2026. novocare.com
- 4KFF. Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition. November 2025. kff.org
- 5American Medical Association. Policy H-440.842, Recognition of Obesity as a Disease. Adopted June 2013. ama-assn.org
- 6Pew Research Center. How Americans View Weight-Loss Drugs and Their Potential Impact on Obesity in the U.S. February 26, 2024. pewresearch.org
- 7NIDDK. Factors Affecting Weight & Health. Last reviewed May 2023. niddk.nih.gov
- 8Endocrine Society. Endocrine Society issues Scientific Statement on obesity's causes. June 26, 2017. endocrine.org
- 9Cleveland Clinic. How Long Should You Be on a GLP-1? May 1, 2026. clevelandclinic.org
- 10Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi.org
- 11Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet. 2026;407(10545):2305-2318. doi.org
- 12FDA. Drugs@FDA approval histories for Byetta®, Saxenda®, Ozempic®, Wegovy® and Foundayo™. fda.gov
- 13Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi.org
- 14Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi.org
- 15Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025;15:100181. nih.gov
- 16LillyDirect. Zepbound® (tirzepatide) self-pay prices. Checked October 6, 2026. lilly.com
- 17LillyDirect. Foundayo™ (orforglipron) self-pay prices. Checked October 6, 2026. lilly.com
- 18UCLA Health. What to know about berberine, the so-called "nature's Ozempic". October 22, 2025. uclahealth.org
- 19Elahi Vahed I, Shahir-Roudi E, Nojumi S, et al. The effect of berberine on obesity indices: a systematic review and meta-analysis. Int J Obes (Lond). 2026;50(1):53-73. doi.org
- 20Cleveland Clinic. Do GLP-1 Patches Work? What To Know. September 17, 2026. clevelandclinic.org
- 21Cleveland Clinic. What Is 'Ozempic Face' and How To Prevent It. March 5, 2025. clevelandclinic.org
- 22FDA. Compounding and the FDA: Questions and Answers. Content current as of September 16, 2025. fda.gov
Product information
- Zepbound® (tirzepatide) is a prescription-only injectable medication FDA-approved for chronic weight management in adults with obesity, or adults with overweight who have at least one weight-related medical condition. It is also approved for the treatment of moderate to severe obstructive sleep apnea in adults with obesity, and should be used in combination with a reduced-calorie diet and increased physical activity.
- Ozempic® (semaglutide) is a prescription-only injectable medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. It is not FDA-approved for weight loss; however, weight reduction has been observed in some individuals with type 2 diabetes using the medication.
- Mounjaro® (tirzepatide) is a prescription-only injectable medication FDA-approved for the treatment of type 2 diabetes. It is not FDA-approved for weight loss; however, weight reduction has been observed in some individuals using the medication.
- Wegovy® (semaglutide) is a prescription-only injectable medication FDA-approved for chronic weight management in adults with obesity, or adults with at least one weight-related medical condition, when used alongside a reduced-calorie diet and increased physical activity.
- All medications require a medical evaluation and prescription from a licensed healthcare provider. Individual results may vary.
Important safety information
- Compounded semaglutide and tirzepatide are prepared by state-licensed pharmacies and are not FDA approved. The FDA does not review their safety, effectiveness or quality, and clinical trial results for brand-name drugs do not carry over to them.
- Semaglutide and tirzepatide carry a boxed warning for a risk of thyroid C-cell tumors, based on animal studies, and are not for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, or who is pregnant. Other warnings include pancreatitis, gallbladder problems, and a higher risk of low blood sugar when combined with insulin or a sulfonylurea. The most common side effects are digestive, such as nausea, vomiting, diarrhea and constipation.
- This is a high-level summary, not a complete list. A licensed clinician will review your health history to decide whether a GLP-1 medication is right for you.
